jama glp-1 WHO Guideline on the Use and Indications of GLP-1 Therapies for the Treatment of Obesity in Adults | Clinical Pharmacy and Pharmacology | JN Learning

New JAMA Data Brief 📊 About 1 in 5 US adults with type 2 diabetes were already using the popular class of medications called glucagon-like peptide 1 (GLP-1) receptor agonists by 2022,

27.19

★★★★☆4.8 (126)

Why GLP-1 Drugs Affect Patients Differently

26.26

★★★★★4.9 (98)

In this podcast, JAMA Medical News Director Jennifer Abbasi and Associate Managing Editor Kate Schweitzer discuss the approval and clinical implications of the first oral #GLP-1 receptor agonist for obesity treatment in

27.98

★★★★★5.0 (157)

Most viewed this week from JAMA Internal Medicine: This Patient Page covers #GLP1 weight-loss medications, focusing on food craving reduction, blood glucose control, dietary strategies, exercise for muscle retention, and lifestyle changes

29.54

★★★★★4.7 (84)

💉 GLP-1 meds help but they’re not the whole story., Exercise remains critical for obesity & diabetes management. , 🏃 Exercise isn’t mainly about burning calories * Exercise burns fewer calories than

21.96

★★★★★4.9 (203)

Study comparing Mounjaro and Ozempic published in JAMA Internal Medicine

29.72

★★★★★5.0 (176)

Genetic differences may help explain why some patients experience greater weight loss or more adverse effects on #GLP1 receptor agonists such as #semaglutide or #tirzepatide, according to a new genome-wide association study

29.00

★★★★★4.8 (132)